The RPS6KB1 antibody is a key tool in studying the ribosomal protein S6 kinase B1 (RPS6KB1), also known as p70S6K, a serine/threonine kinase central to the mTOR (mechanistic target of rapamycin) signaling pathway. This kinase regulates critical cellular processes, including protein synthesis, cell growth, proliferation, and metabolism by phosphorylating downstream targets like the S6 ribosomal protein. Dysregulation of RPS6KB1 is implicated in cancer, diabetes, and aging-related diseases, making it a focal point in therapeutic research, particularly for mTOR-targeted therapies.
The antibody detects RPS6KB1 in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), enabling researchers to assess protein expression, localization, and activation status. Phospho-specific RPS6KB1 antibodies (e.g., targeting Thr389) are widely used to monitor its activation by mTORC1. a critical step in pathway signaling. These antibodies aid in studying cellular responses to growth factors, nutrients, and stress, as well as evaluating drug efficacy in preclinical models.
Commercial RPS6KB1 antibodies are available as monoclonal or polyclonal variants, with validation often performed in knockout cell lines or tissues to ensure specificity. Their application spans cancer research (e.g., breast, prostate cancers), metabolic studies, and neurodegeneration, reflecting the kinase's broad regulatory role. Proper controls and optimization remain essential due to potential cross-reactivity with homologous kinases like RPS6KB2.